Member Info for RollingInIt

Teabiscuit

Totally agree with your analysis.

He's a negative Jonah. The antipodes of a successful public advertising campaign for an asset. Ridiculous approach.

Bet he wouldn't advertise his house for sale, as:

"S.h.i.t house, lot's of remedial work needed, value likely to drop again, poor area and naff neighbours.

Hope you like it because it should come out alright in the end.

Offers invited but I'm not expecting much."

Today it bounced off the repeat support of 139/140 again that's been in play numerous times since the 1st of May.

It featured prior to the rise to 300p and subsequent to the placing announcement, almost immediately after, and numerous times since then.

The downtrend in play since the peak of 300p will be broken and reversed to an uptrend when it breaches around 170/175p.

No reason why this can't be achieved in the near term and given sentiment combined with news are volume creators and the key drivers to price action, based on the expected news relating to further approvals and/or sales, the timing would make sense.

Sneaky

Yes, which is why I introduced as being in the NCYT, RNS.

To demonstrate that global demand for COV19 tests are increasing and set to continue for a long while yet.

Dreammachine

Agree, it's very early days in the lifecycle of COV19 tests demand.

In the statement by NCYT only a couple of weeks ago:

______
The Directors believe the significant demand for the Company's COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase.
______

Global demand continues to increase.

Separately and unrelated to Dreammachine.

The latest update on the operating profit at NCYT is not 'at least 60%', it's less and only a proportion of that will be realised. Additionally, they're now having to rely on the manufacturing services of BioPharma and Biofortuna which would reduce the percentages further still, as both providers will require their own margin.

Scart

You may wish to waste your hours unproductively.

I don't.

Too much time already spent here rebuffing uninteresting, agenda led nonsense.

Scart

Learn when to accept an olive branch.

You wouldn't want me to follow up on your pointless suggestion. More than capable.

Move on.

Scart

You're being played. The Jonah knows it and so do I amongst others, with his little divide and conquer manoeuvre.

It's irrelevant to the progress of GDR and you're pointing your finger at the wrong posters.

Happy to move on.

Scart

Not quite the full picture when chastising Teabiscuit. What was actually written was 'until then it's risky', referring to sales.

All stocks are risky, however GDR is no less risky than NCYT was, when valued at twice the GDR market cap in February and no less risky than AVCT is now, valued at five times the market cap of GDR, with no sales yet and not even a product yet at AVCT.

You're refusing to see the continual snide attempts at a negative slant and Teabiscuit can clearly see the buffoonery at play, as can I and many others.

There is much to be excited about with the latest developments at GDR and there are valuation yardsticks to recognise in the sector, shedding light on the share price prospects of GDR in the near term and the intent to completely drown out the justifiable enthusiasm of holders here should be challenged, as Teabiscuit has. The waffling bs posts claiming faux positivity and innocence, have as heady a stench of insincerity as the repeat attempts at negativity.

Obvious.

Final retort, Magsy

You're getting more desperate with every fatuous rejoinder you concoct.

NCYT provide tests to the NHS.

It's not rocket science.

As an aside, I don't believe you've ever been lucky and certainly not in your failed attempts at disproving facts. You're a time waster and I've devoted far too much of my time in your direction already.

I don't need any 'help', Magsy, you do.

Had you bothered to regularly listen to the daily Coronavirus statements and also the analysis of the track and trace objectives, you wouldn't have claimed falsely that the 30% false negatives emerging from the current tests don't exist.

Anyway, enough.

Debating with an idiot is fruitless, if for no other reason than you don't have the cranial capacity to recognise your own idiocy.

The share price appreciation will happen despite your inane contributions, upsetting as that may be for you.

Magsy

You just continue confirming that you're not the brightest. It's a gift that keeps on giving.

The market cap at NCYT rose to £152 Million in February with a tiny sales volume of 40,000 tests and a CE Mark.

In simple terms, which you need, that's double the current market cap of GDR, who also have a CE Mark.

That's prior to a £90 Million sales value and their margin would have been zero on the 40,000, so it's the antipodes of a 'premature comparison'.

As far as the 30% false positives, you need, yet again, to research more. I'm not doing it for you, mainly because of your wish to behave repeatedly like a buffoon.

The embarrassment is yours but I think you know that already and why you're trying so desperately ,but failing miserably, to disprove the positive distinctions and advantages that GDR have.

Flyingmachine

It was on the BBC News in April.

Accepted, the circumstance may have improved for them since then but the description at the time was 'barely breaking even, if anything making a loss', so my previous reference to the margin position there was measured.

Neither is it to criticise other test producers, it's to provide one of the distinctions at GDR, which is from the outset, they have a £ Multi Billion partner, GE/Cytiva, as do AVCT, with a global presence in 40 countries and with over 7,000 staff, and they have the production capacity and margin. At NCYT, that wasn't the case but it didn't hold back their rapid market valuation increase.

Yet another demonstration of GDR's gross undervaluation currently.

Doggy

That's generous but thanks for the sentiment.

The NCYT CEO openly admitted it in an interview a while back that they were just breaking even on their tests and that they were struggling to source parts.

You can check back by listening to all of their interviews. Research.

Why a number of alleged 'holders' need further 'research' by others to 'convince' them and to demonstrate why GDR is hugely undervalued and why the GDR share price will rise dramatically, is beyond me.

Here are just a few facts to demonstrate why.

GDR is currently valued at £ 78 Million.

On the 17th of February, NCYT announced their CE Mark for their test along with a very small number of orders, (40,000), and their market cap responded by rising to £152 Million, double that of the current GDR market cap.

GDR also now have the CE Mark for their test allowing immediate commercial sales and it is now also known, in hindsight, that the NCYT test profit margins were near to zero and their production capacity was compromised, whereas the GDR margins are healthy as is their production capacity in advance..

Current tests, some of which will have been supplied by NCYT, have been shown to have a false negative rate of around 30%, rendering high risk for continuing infection growth, whereas the GDR test has a greater accuracy.

Cytiva, GDR's partner, was responsible for the majority of FDA approvals in the sector during 2019.

The FDA have an MOU with the Bill Gates Foundation and the Bill Gates Foundation fund WHO with tens of $ Billions. Wheels within wheels.

Separately, AVCT are valued at around £400 Million with no test ready yet for commercial use and therefore no sales yet.

Yes, they have other facets to their portfolio, but so do GDR.

It's not an 'it's us or them' relating to stocks that produce tests, it's an 'us AND them' that's needed. The global demand for tests is so vast that there's room for many providers, far more than exist at present.

These, in my opinion, are just a few reasons why GDR is hugely undervalued and why the share price in GDR will rise dramatically toward a fairer valuation.

Scart

What you can determine is where the market cap should be, based on same sector valuations and given the far greater margins at GDR and the partnership with Cytiva, the potential for the market cap at GDR to exceed that of NCYT.

With reference to Magsy, there is no time qualification for highlighting an intentional disrupter, determined to write repetitive nonsense.

It's obvious within seconds to the reader and it's clear to me that he's trolling.

We all have individual opinions, you're fully entitled to yours and likewise, so am I, regardless of time spent on a thread.

Those that care the most, tell you the truth Magsy.

Consider it a mission of compassion. I'm all heart.

Weak attempt, Magsy.

The fact remains, in yet another poor display of faux negativity, you were called out on an inane statement, a specialism of yours.

You're not the brightest but sincerely appreciate your efforts.

Enjoy the increasing valuation at GDR.

Magsy

It's really quite simple, which should appeal to your ability to understand.

NCYT's CEO openly admitted that they were breaking even on their tests, so even with no sales, GDR would be on a par. Mainly because NCYT lacked the capacity for production and struggled to source parts for tests.

In addition, the partnership that GDR has with a US major, Cytiva, puts it head and shoulders above.

However, despite your disgust at the prospect, GDR will have sales and make a very healthy 60% margin.

Now, I know, according to you, market caps are just numbers with nothing to back them up and on that basis, the stock market in it's entirety shouldn't exist.

How we all laughed.

Glad to know you're trying to learn but I fear you will remain a m.o.r.o.n.

Copied from Ad ....

Demonstrates how undervalued GDR is and the target prices.

______

'The potential high here is far greater than that.

To match the current market cap at NCYT, the GDR share price would be £4.60.

To match NCYT's market cap at it's peak, the GDR share price would be £7.80.

To match the current market cap at AVCT, the GDR share price would be £10.00.'